Tumor lysis syndrome

Tumor lysis syndrome
Synonyms	TLS
Pronounce	N/A
Specialty	N/A
Symptoms	Hyperuricemia, Hyperkalemia, Hyperphosphatemia, Hypocalcemia, Acute kidney injury
Complications	Renal failure, Cardiac arrhythmia, Seizures
Onset	Typically occurs after chemotherapy or radiation therapy
Duration	Varies, can be acute
Types	N/A
Causes	Rapid breakdown of tumor cells
Risks	High tumor burden, high cell turnover rate, sensitivity to treatment
Diagnosis	Based on laboratory findings and clinical presentation
Differential diagnosis	Sepsis, Dehydration, other causes of electrolyte imbalance
Prevention	Hydration, Allopurinol, Rasburicase
Treatment	Intravenous fluids, Electrolyte management, Dialysis if necessary
Medication	N/A
Prognosis	Good with prompt treatment, but can be life-threatening
Frequency	More common in hematologic malignancies such as acute lymphoblastic leukemia and Burkitt's lymphoma
Deaths	N/A

Tumor Lysis Syndrome Tumor Lysis Syndrome (TLS) is a potentially life-threatening condition that occurs when a large number of cancer cells die within a short period, releasing their contents into the bloodstream. This can lead to metabolic abnormalities and acute renal failure. TLS is most commonly associated with the treatment of hematologic malignancies such as leukemia and lymphoma, but it can also occur spontaneously.

Pathophysiology

The rapid destruction of tumor cells leads to the release of intracellular ions and metabolic byproducts into the bloodstream. The key components released include:

• Potassium: Hyperkalemia can occur due to the release of intracellular potassium, leading to cardiac arrhythmias.
• Phosphate: Hyperphosphatemia results from the release of phosphate, which can precipitate with calcium, leading to hypocalcemia and renal failure.
• Uric Acid: The breakdown of nucleic acids results in hyperuricemia, which can lead to the formation of uric acid crystals in the renal tubules, causing acute kidney injury.
• Calcium: Hypocalcemia occurs due to the precipitation of calcium with phosphate, which can cause neuromuscular irritability and cardiac dysfunction.

Risk Factors

Patients at high risk for TLS include those with:

• High tumor burden
• High proliferation rate of the tumor
• High sensitivity to chemotherapy
• Pre-existing renal impairment

Clinical Presentation

Symptoms of TLS can vary but often include:

• Nausea and vomiting
• Diarrhea
• Muscle cramps or spasms
• Seizures
• Cardiac arrhythmias
• Acute renal failure

Diagnosis

TLS is diagnosed based on laboratory findings and clinical criteria. The Cairo-Bishop definition is commonly used, which includes:

• Laboratory TLS: Abnormalities in two or more serum values (uric acid, potassium, phosphate, calcium) within three days before or seven days after chemotherapy.
• Clinical TLS: Laboratory TLS plus one or more of the following: increased serum creatinine, cardiac arrhythmia, or seizure.

Management

Management of TLS involves both prevention and treatment:

• Hydration: Aggressive intravenous hydration to maintain high urine output and prevent renal failure.
• Allopurinol: Used to prevent the formation of uric acid by inhibiting xanthine oxidase.
• Rasburicase: An enzyme that converts uric acid to allantoin, which is more soluble and easily excreted.
• Electrolyte Management: Correction of hyperkalemia, hyperphosphatemia, and hypocalcemia as needed.
• Dialysis: May be required in severe cases to manage renal failure and electrolyte imbalances.

Prognosis

With prompt recognition and treatment, the prognosis of TLS can be favorable. However, if left untreated, it can lead to severe complications and even death.

Also see

• Leukemia
• Lymphoma
• Acute kidney injury
• Hyperkalemia
• Hyperphosphatemia
• Hypocalcemia
• Hyperuricemia